Last updated on November 2019

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Brief description of study

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.

Clinical Study Identifier: NCT03559192

Find a site near you

Start Over

Emovis GmbH

Berlin, Germany
  Connect »